Quote | Super Quote
56064 HS#HSI RP2112X (R BEAR)
RT Nominal down0.214 -0.018 (-7.759%)

16/07/2021 17:56

CSPC Pharma (01093) product gets clinical trial approval

[ET Net News Agency, 16 July 2021] CSPC Pharmaceutical Group Limited (01093) said
"SYSA1801", an antibody-drug conjugate developed by the group, has obtained approval of
its Investigational New Drug Application (IND) from the U.S. Food and Drug Administration
(FDA) to conduct clinical trials for advanced pancreatic cancer with positive Claudin 18.2
expression. The Phase I clinical trial will evaluate the safety, tolerability,
pharmacokinetics and preliminary efficacy of SYSA1801.
SYSA1801 is novel (first-in-class) anti-Claudin 18.2 monoclonal antibody-drug conjugate.

Remark: Real time quote last updated: 20/10/2021 11:48
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2021 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.